Hikma Pharmaceuticals PLC Annual report 2010 notes to tHe ConsoLIdAted FInAnCIALstAtements Continued 34. net CAsH From oPerAtInG ACtIvItIes 2010 2009 $000 $000 Profit before tax 120,982 94,787 Adjustments for: depreciation and amortisation of: Property, plant and equipment 29,091 25,199 Intangible assets 9,342 8,949 Gain on revaluation of previously held equity interest 7,176 Loss on disposal of property, plant and equipment 376 236 Gain on disposal of intangible assets 162 903 movement on provisions 2,488 761 movement on deferred income 159 201 Cost of equity settled employee share scheme 4,473 4,616 Finance income 346 514 Interest and bank charges 13,856 12,827 Cash flow before working capital 172,765 145,757 Change in trade and other receivables 10,689 29,949 Change in other current assets 322 190 Change in inventories 19,295 8,278 Change in trade and other payables 16,102 24,262 Change in other current liabilities 3,091 3,164 Cash generated by operations 177,492 134,766 Income tax paid 32,657 15,787 Net cash generated from operating activities 144,835 118,979 35.
ContInGent LIABILItIes The Group was contingently liable for letters of guarantee and letters of credit totalling USD 119.7 million 2009: USD 62.4 million.
The integrated nature of the Groups worldwide operations, involving significant investment in research and strategic manufacture at a limited number of locations, with consequential cross-border supply routes into numerous end-markets, gives rise to complexity and delay in negotiations with revenue authorities as to the profits on which individual Group companies are liable to tax.
Disagreements with, and between, revenue authorities as to intra-Group transactions, in particular the price at which goods and services should be transferred between Group companies in different tax jurisdictions, has the potential to produce conflicting claims from revenue authorities as to the profits to be taxed in individual territories.
In common with many other companies in the pharmaceutical industry the Group is involved in various legal proceedings considered typical toits business, including litigation relating to employment, product liability and other commercial disputes.
As reported in 2009, West-Ward Pharmaceutical Corp. was a co-defendant, with four other generic pharmaceutical manufacturers, in litigation brought by Mutual Pharmaceutical Company, Inc. regarding the continued sale by West-Ward Pharmaceutical Corp. and the others of generic oral TM colchicine in the United States, following the approval by the FDA of Mutuals Colcrys colchicine product the Claim.
On 18 October 2010 the Group announced that the dispute between West-Ward Pharmaceutical Corp. and Mutual Pharmaceutical Company, Inc. relating to the sale of oral colchicine tablets hadbeen resolved to the parties mutual satisfaction.
